Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection
Author
Chen, C.Parthasarathy, S.
Leung, J.M.
Wu, M.J.
Drake, K.A.
Ridaura, V.K.
Zisser, H.C.
Conrad, W.A.
Tapson, V.F.
Moy, J.N.
deFilippi, C.R.
Rosas, I.O.
Prabhakar, B.S.
Basit, M.
Salvatore, M.
Krishnan, J.A.
Kim, C.C.
Affiliation
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of ArizonaIssue Date
2023-10-16
Metadata
Show full item recordPublisher
Frontiers Media SACitation
Chen C, Parthasarathy S, Leung JM, Wu MJ, Drake KA, Ridaura VK, Zisser HC, Conrad WA, Tapson VF, Moy JN, deFilippi CR, Rosas IO, Prabhakar BS, Basit M, Salvatore M, Krishnan JA and Kim CC (2023) Distinct temporal trajectories and risk factors for Post-acute sequelae of SARS-CoV-2 infection. Front. Med. 10:1227883. doi: 10.3389/fmed.2023.1227883Journal
Frontiers in MedicineRights
© 2023 Chen, Parthasarathy, Leung, Wu, Drake, Ridaura, Zisser, Conrad, Tapson, Moy, deFilippi, Rosas, Prabhakar, Basit, Salvatore, Krishnan and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Background: The understanding of Post-acute sequelae of SARS-CoV-2 infection (PASC) can be improved by longitudinal assessment of symptoms encompassing the acute illness period. To gain insight into the various disease trajectories of PASC, we assessed symptom evolution and clinical factors associated with the development of PASC over 3 months, starting with the acute illness period. Methods: We conducted a prospective cohort study to identify parameters associated with PASC. We performed cluster and case control analyses of clinical data, including symptomatology collected over 3 months following infection. Results: We identified three phenotypic clusters associated with PASC that could be characterized as remittent, persistent, or incident based on the 3-month change in symptom number compared to study entry: remittent (median; min, max: −4; −17, 3), persistent (−2; −14, 7), or incident (4.5; −5, 17) (p = 0.041 remittent vs. persistent, p < 0.001 remittent vs. incident, p < 0.001 persistent vs. incident). Despite younger age and lower hospitalization rates, the incident phenotype had a greater number of symptoms (15; 8, 24) and a higher proportion of participants with PASC (63.2%) than the persistent (6; 2, 9 and 52.2%) or remittent clusters (1; 0, 6 and 18.7%). Systemic corticosteroid administration during acute infection was also associated with PASC at 3 months [OR (95% CI): 2.23 (1.14, 4.36)]. Conclusion: An incident disease phenotype characterized by symptoms that were absent during acute illness and the observed association with high dose steroids during acute illness have potential critical implications for preventing PASC. Copyright © 2023 Chen, Parthasarathy, Leung, Wu, Drake, Ridaura, Zisser, Conrad, Tapson, Moy, deFilippi, Rosas, Prabhakar, Basit, Salvatore, Krishnan and Kim.Note
Open access journalISSN
2296-858XPubMed ID
37908849Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.3389/fmed.2023.1227883
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2023 Chen, Parthasarathy, Leung, Wu, Drake, Ridaura, Zisser, Conrad, Tapson, Moy, deFilippi, Rosas, Prabhakar, Basit, Salvatore, Krishnan and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Related articles
- A longitudinal SARS-CoV-2 biorepository for COVID-19 survivors with and without post-acute sequelae.
- Authors: LaVergne SM, Stromberg S, Baxter BA, Webb TL, Dutt TS, Berry K, Tipton M, Haberman J, Massey BR, McFann K, Alnachoukati O, Zier L, Heacock T, Ebel GD, Henao-Tamayo M, Dunn J, Ryan EP
- Issue date: 2021 Jul 13
- Clinical features and burden of post-acute sequelae of SARS-CoV-2 infection in children and adolescents: an exploratory EHR-based cohort study from the RECOVER program.
- Authors: Rao S, Lee GM, Razzaghi H, Lorman V, Mejias A, Pajor NM, Thacker D, Webb R, Dickinson K, Bailey LC, Jhaveri R, Christakis DA, Bennett TD, Chen Y, Forrest CB
- Issue date: 2022 May 25
- A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings.
- Authors: Sneller MC, Liang CJ, Marques AR, Chung JY, Shanbhag SM, Fontana JR, Raza H, Okeke O, Dewar RL, Higgins BP, Tolstenko K, Kwan RW, Gittens KR, Seamon CA, McCormack G, Shaw JS, Okpali GM, Law M, Trihemasava K, Kennedy BD, Shi V, Justement JS, Buckner CM, Blazkova J, Moir S, Chun TW, Lane HC
- Issue date: 2022 Jul
- Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in the Inpatient and Outpatient Setting in a Diverse Cohort.
- Authors: Yoo SM, Liu TC, Motwani Y, Sim MS, Viswanathan N, Samras N, Hsu F, Wenger NS
- Issue date: 2022 Jun
- Plasma proteomics show altered inflammatory and mitochondrial proteins in patients with neurologic symptoms of post-acute sequelae of SARS-CoV-2 infection.
- Authors: Hanson BA, Visvabharathy L, Orban ZS, Jimenez M, Batra A, Liotta EM, DeLisle RK, Klausner JD, Cohen P, Padhye AS, Tachas G, Koralnik IJ
- Issue date: 2023 Nov

